Constructed a systems medicine framework for repurposing drugs for COVID-19 in people with type 2 diabetes and hypertension. Cellular antiviral targets from virus-host protein interactions have been identified for each drug and then evaluated them with gene functional enrichment analysis. A total of 174 repurposable drugs were identified by quantifying the interplay between virus-host protein interactions and drug targets in the human protein network. As a result, there are no involvements in host gene expression, biological processes, and side effects for fostamatinib. It suggests that fostamatinib is a repurposed drug for the treatment of systemic COVID-19 patients with clinical comorbidities (T2DM and HT).
Bharathidasan University
Professor
Acces sibility Controls